AU5140193A - Inhibition of cyst formation by cytoskeletal specific drugs - Google Patents

Inhibition of cyst formation by cytoskeletal specific drugs

Info

Publication number
AU5140193A
AU5140193A AU51401/93A AU5140193A AU5140193A AU 5140193 A AU5140193 A AU 5140193A AU 51401/93 A AU51401/93 A AU 51401/93A AU 5140193 A AU5140193 A AU 5140193A AU 5140193 A AU5140193 A AU 5140193A
Authority
AU
Australia
Prior art keywords
cytoskeletal
inhibition
specific drugs
cyst formation
cyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU51401/93A
Inventor
David D. L Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of AU5140193A publication Critical patent/AU5140193A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU51401/93A 1992-09-25 1993-09-24 Inhibition of cyst formation by cytoskeletal specific drugs Abandoned AU5140193A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95127092A 1992-09-25 1992-09-25
US951270 1992-09-25
PCT/US1993/009124 WO1994008041A1 (en) 1992-09-25 1993-09-24 Inhibition of cyst formation by cytoskeletal specific drugs

Publications (1)

Publication Number Publication Date
AU5140193A true AU5140193A (en) 1994-04-26

Family

ID=25491512

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51401/93A Abandoned AU5140193A (en) 1992-09-25 1993-09-24 Inhibition of cyst formation by cytoskeletal specific drugs

Country Status (4)

Country Link
EP (1) EP0663958A4 (en)
AU (1) AU5140193A (en)
CA (1) CA2145680A1 (en)
WO (1) WO1994008041A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750495A (en) * 1996-03-26 1998-05-12 The Regents Of The University Of California Treatment of cystic disease with TNF-α
WO1998031380A1 (en) * 1997-01-16 1998-07-23 Washington State University Research Foundation Phalloidin derivatives and analogs to treat congestive heart failure
US7252950B1 (en) * 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US6433187B1 (en) 1998-12-17 2002-08-13 Tularik Inc. Certain polycyclic compounds useful as tubulin-binding agents
ATE300947T1 (en) * 1998-12-18 2005-08-15 Scios Inc TREATMENT OF DISEASES INVOLVING CYST FORMATION
EP1607744A3 (en) * 1998-12-18 2009-09-30 Scios Inc. Treatment of diseases involving cyst formation with combinations comprising a PTBR agonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401651A (en) * 1979-04-18 1983-08-30 Knutson Richard A Wound-healing compositions containing povidone-iodine
US4515794A (en) * 1981-10-09 1985-05-07 Baylor College Of Medicine Mitotic inhibitors preventing posterior lens capsule opacification
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US4695471A (en) * 1984-07-30 1987-09-22 Sloan-Kettering Institute For Cancer Research Breast cyst fluid screening method for cancer risk assessment
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5122371A (en) * 1986-12-09 1992-06-16 Chaslow Fred I Biologically active agent having antihypertensive activity in mammals
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
US5147783A (en) * 1988-05-27 1992-09-15 Ube Industries, Ltd. Methods to screen for ovarian cancer and myocardial infarction
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms

Also Published As

Publication number Publication date
CA2145680A1 (en) 1994-04-14
WO1994008041A1 (en) 1994-04-14
EP0663958A4 (en) 1999-10-20
EP0663958A1 (en) 1995-07-26

Similar Documents

Publication Publication Date Title
AU5621594A (en) 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
AU5453994A (en) Inhibitors of farnesyl-protein transferase
AU3888793A (en) Novel medicament
AU3634095A (en) Inhibition of hemoflagellates by camptothecin compounds
AU8726991A (en) Reduction or prevention of sensitization to drugs
AU2265895A (en) Inhibition of liver cancer by the use of gnrh and gnrh analogs
AU4156993A (en) Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
AU3728889A (en) Corrosion inhibition
AU7456396A (en) Inhibition of amyloidosis by 9-acridinones
AU3808289A (en) Pharmaceutical compositions for the inhibition of tumor metastasis
AU3584093A (en) Diaminopyridine compounds for the inhibition of protein glycosylation
AU4788396A (en) Inhibition of angiogenesis using interleukin-12
AU5323694A (en) 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
AU8156094A (en) Methods of inhibiting breast disorders
AU641600B1 (en) Synthesis of desflurane
AU4801493A (en) New derivatives of neuraminic acid
AU5188093A (en) Fungicidal derivatives of 2-alkoxy-2-imidazolin-5-ones
AU5184393A (en) Substituted derivatives of diaminophthalimide
HUP9901055A3 (en) Preparation of clavulanate salts
AU5140193A (en) Inhibition of cyst formation by cytoskeletal specific drugs
AU3922493A (en) Inhibition of P70 S6 kinase
AU6396394A (en) Products of the inhibition of advanced glycosylation
AU3691093A (en) Methods of inhibiting the growth of multidrug resistant tumors
AU3763593A (en) Resolution of emulsions
AU3359493A (en) Determination of haptens